Cargando…
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
Although classical Hodgkin lymphoma (cHL) is usually curable, 20–30% of the patients experience treatment failure and most of them are typically treated with salvage chemotherapy and autologous stem cell transplantation (autoSCT). However, 45–55% of that subset further relapse or progress despite in...
Autores principales: | Vassilakopoulos, Theodoros P., Chatzidimitriou, Chrysovalantou, Asimakopoulos, John V., Arapaki, Maria, Tzoras, Evangelos, Angelopoulou, Maria K., Konstantopoulos, Kostas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721364/ https://www.ncbi.nlm.nih.gov/pubmed/31362369 http://dx.doi.org/10.3390/cancers11081071 |
Ejemplares similares
-
Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2020) -
Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma
por: Chatzidimitriou, Chrysovalantou, et al.
Publicado: (2021) -
Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2022) -
P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2022) -
Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2023)